{"name":"BioRay Pharmaceutical Co., Ltd.","slug":"bioray-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"bioray.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"BRY812 for injection","genericName":"BRY812 for injection","slug":"bry812-for-injection","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"Perjeta","genericName":"Perjeta","slug":"perjeta","indication":"HER2-positive carcinoma of breast","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"HS627","genericName":"HS627","slug":"hs627","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"BR101","genericName":"BR101","slug":"br101","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"BRY812 for injection","genericName":"BRY812 for injection","slug":"bry812-for-injection","phase":"phase_2","mechanism":"BRY812 for injection is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"HS627","genericName":"HS627","slug":"hs627","phase":"phase_3","mechanism":"HS627 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"BR101","genericName":"BR101","slug":"br101","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Perjeta","genericName":"Perjeta","slug":"perjeta","phase":"marketed","mechanism":"Receptor tyrosine-protein kinase erbB-2","indications":["HER2-positive carcinoma of breast","HER2-positive colon cancer","HER2-positive rectal cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPWEdKT1UwaGh0T0wwNzRsRG1KNVFRbGxGUVFuVGhpSmxxaklOUC0zRHlBeTZyZy1pckpXdWwtY1h5d3B3ZF9temJONHNIdzk1WUN4aXZHekxkaXU0UlVTRUMyS3NJYlpjenhLaE95N3FlZ3RmVktsY3ZoY3JSM0trX1hpQ3RhWC1zSjBLS1pORjVYaEdteVQzM0FhNS00SHNZRGpsZHcyQ1ZxUWM?oc=5","date":"2026-04-01","type":"deal","source":"富途牛牛","summary":"SiHuan Pharmaceutical (00460) and BioRay Pharma (02315) have reached a strategic partnership to accelerate the development of innovative drugs in multiple fields, including weight loss, through an AI-","headline":"SiHuan Pharmaceutical (00460) and BioRay Pharma (02315) have reached a strategic partnership to accelerate the developme","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPcFZ3VkYtaHBTM2VuaDBqZ1gxa3RLM3JxRWd4SGpEUm1XdmcxejI0RV8xc2ZJaDBUR2NNN2hEeWx6MGdSY2V2UW15akNPbFJYYWo5ZVRDTkxQd2lobWtlNVpacldWblJiN3Q2dE9qOGZxSFpCTS0yRk55VWNDdDQxY1EtRG1NQldlM0w4M0Zrb2E5eXp6cU9YLQ?oc=5","date":"2026-01-09","type":"pipeline","source":"The Pharma Letter","summary":"BioRay Biopharmaceutical files for Hong Kong IPO | Biotechnology | The Pharmaletter - The Pharma Letter","headline":"BioRay Biopharmaceutical files for Hong Kong IPO | Biotechnology | The Pharmaletter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOdF8yTXJlNGFhOHdaMGItM3pkRVVxSDJ1XzlUcHFEamVvSXI0dlZHTjB1ZXQwZHM1Y21sVDlJTEt2a3NEQUo5RV95TTctYUtXcDlVNDFabDVMa3F3UFRwU0RRRFl2cTdyc1Z4S3VSeFJyY2pMZWQ1akxaU3dBeS1ETUJuQmlrS2hRSVRldFRLOUdaUUY0dlE3R2I3Uk9HczZEZDFtZXJhVQ?oc=5","date":"2025-11-18","type":"regulatory","source":"BioWorld News","summary":"Henlius, Organon win US FDA approval of first Perjeta biosimilar - BioWorld News","headline":"Henlius, Organon win US FDA approval of first Perjeta biosimilar","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQdTRXcDJUbzI2U195bTZrQ1NzTGhISDVFaXJsUzNpcUVBc0dJNTVRU2NveWNoU0N3bkpPY3ZvTGJvNHRScW81S1JmQWtnQ3dHNkRaUGVkRHZBblpBRmJYeHE1dnQ3UGRDS2FQZXZKUkZLa2JRQS1GZFFELXZXMDRQMzFYVkRLeGE2TUY5NVFfYUxxb2ZIQnVQeFVsTVN4QVE2Z2ZUVm1IbmtTNlRGSXd1cjlfd194aUpYZ2RLQm00WS1hbFhsR3RuVUJIZ05udW9K?oc=5","date":"2025-02-11","type":"trial","source":"BioPharma APAC","summary":"China's BioRay Secures NMPA Nod for Clinical Trials of BR111, a First-in-Class Anti-ROR1 ADC - BioPharma APAC","headline":"China's BioRay Secures NMPA Nod for Clinical Trials of BR111, a First-in-Class Anti-ROR1 ADC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOX3Q1M3hlZjB0QWJuVTZPNFpseUxwbU14bzJfanpzVG1rMGV6TlVIOFcwTUJYVTdoamF4ejVKeDlBSlZ1bXI2X2p4SFpGbVhQOURZYUJRVlFpRzZ2LS05cHZwbGQ3X3piT1Rmbl95MWM0RnVra1dhdUh2aGk5eWVkamFJSU9WaGJCU2w1YTlQdzBQREJHZWtRdGRxa3E2NG8?oc=5","date":"2024-11-30","type":"pipeline","source":"The Pharma Letter","summary":"UCB closes portfolio divestment and focuses on new launch in China - The Pharma Letter","headline":"UCB closes portfolio divestment and focuses on new launch in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5kRTFuYjdhT0hlMFR3bHJGcFJ0S3d0ZDB1bzN2NDBFY0YwMWlfTk5IbHhRaVA2LTRkZFowcU03Z0NPY3ZDajVxU0NncU5IdzFONklXaURvT3B4M1F0d2hV?oc=5","date":"2024-02-20","type":"regulatory","source":"nature.com","summary":"Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA - nature.com","headline":"Targeted drug approvals in 2023: breakthroughs by the FDA and NMPA","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPeWJsbW9iS3dtbndzR19JbTByN096a3hxaV90SUxMTTNLM2F4d0RyakI5Mlk0YTB3V1RTdHdyWDdsOU9ValpFVFpJZ01qRFdVNUNtNWltc3BRc01lRi1sZjRtSTlzdm9wcEwtZ1Rsa1RRZnlEOFUyRmEtb04zd0dsZmpuRTR1U1hCNUpfY0xid1B5aG91Y3hiUFJBZHF2a2dJQjhuMzdOWFYzcUc4TVcwOFRJNmdzY09CN1ZGcDNoSks?oc=5","date":"2023-09-14","type":"regulatory","source":"BioPharma APAC","summary":"BioRay's Zuberitamab (Anruixi®) First Domestic Anti-CD20 Antibody Approved in China - BioPharma APAC","headline":"BioRay's Zuberitamab (Anruixi®) First Domestic Anti-CD20 Antibody Approved in China","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNMndhNXJqSXJnejFfb2lRbEtQWUpNSTJDbXpDdmlTQW91RnVaWEpvU1dmZ1FKbTJLZld2NXFjQ0FiNGRtR1ExU1MtaHA4d2FpNDBrb2lpc1ZqaE9Kd3NqZ2VrelA1OWYwdzRvR3E1Sk1SXzJuX3l0RHJNYk1TbXZJN2g5QmwwZzVnbjhUYQ?oc=5","date":"2023-03-09","type":"pipeline","source":"Private Equity Stakeholder Project PESP","summary":"Private Equity Healthcare Acquisitions – January 2023 - Private Equity Stakeholder Project PESP","headline":"Private Equity Healthcare Acquisitions – January 2023","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":1,"phase_3":1,"phase_1":1,"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}